Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy

Eur J Cancer. 2023 Jul:187:161-163. doi: 10.1016/j.ejca.2023.03.030. Epub 2023 May 9.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Brain Neoplasms* / drug therapy
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / secondary
  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Immunoconjugates* / therapeutic use
  • Quinazolines / therapeutic use
  • Receptor, ErbB-2
  • Trastuzumab / therapeutic use

Substances

  • tucatinib
  • Trastuzumab
  • Quinazolines
  • Immunoconjugates
  • Receptor, ErbB-2